Skip to Content


Main Content

Blood Advances | 2020

Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase.

Gupta V, Kennedy JA, Capo-Chichi J-M, Kim S, Hu Z-H, Alyea EP, Popat UR, Sobecks RM, Scott BL, Gerds AT, Salit RB, Deeg HJ, Nakamura R, Saber W

PMID: 33170935

Related Articles

CIBMTR Study #: CK15-03a

Working Committee: Chronic Leukemia